Faculty

David T. Rubin, MD, FACG, AGAF, FACP, FASGE (Chair) Joseph B. Kirsner Professor of Medicine Section Chief, Gastroenterology, Hepatology and Nutrition Co-Director, Digestive Diseases Center University of Chicago Medicine Chicago, IL

Miguel Regueiro, MD, AGAF, FACG, FACP Professor and Chair Department of Gastroenterology, Hepatology & Nutrition The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology Cleveland Clinic Cleveland, OH

Co-provided by

Statement of Need

Improved long-term clinical outcomes in patients with ulcerative colitis (UC) include sustained clinical remission, decreased need for surgery, decreased hospitalization rates, and reduced risk of colon cancer. Mucosal healing is reported to be associated with these improved outcomes, with some experts suggesting that histologic inflammation is a better predictor of future clinical relapse than endoscopic appearance alone, as endoscopic findings are not always consistent with histologic activity and tend to underestimate the depth of mucosal damage relative to the histologic findings.

Clinical studies have demonstrated that histologic improvements may be associated with better clinical outcomes, including reduced colorectal cancer and relapse rates.

This CME Outfitters symposium features expert faculty in an interactive discussion utilizing real-life case scenarios to highlight optimal approaches to treat and monitor patients with UC.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Evaluate the efficacy of current and emerging UC treatments in achieving mucosal healing and steroid-free remission.
• Apply approaches to achieve mucosal healing in patients with UC.
• Implement strategies to monitor patients with UC for endoscopic and histologic disease activity in order to guide therapy.

Financial Support

Supported by educational grants from Genentech and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Gastroenterologists, gastroenterology fellows, physician assistants, nurse practitioners, and nurses.

Credit Information

CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

USF Health designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours. 

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

ABIM MOC Credit:
MOC Points available for Internal Medicine and General Medicine Board Certified Physicians.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Within 60 days of the end of the activity, ABIM MOC points will be reported on your behalf.

For more information about ACCME accreditation and ABIM MOC for this activity, please email cpdsupport@health.usf.edu.

Learning Format:

Live activity

By providing your ABIM number, you consent to have CME Outfitters and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit: https://www.cmeoutfitters.com/privacy-and-confidentiality-policy/.

Disclosure Declaration

It is the policy of USF Health and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Arena Pharmaceuticals, Inc.; Biomica; Bristol-Myers Squibb Company; Dizal Pharmaceutical; Eli Lilly and Company; Ferring Pharmaceuticals Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Medtronic; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Pfizer Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and TARGET PharmaSolutions, Inc. He receives other financial or material support as a member of the Board of Trustees for the American College of Gastroenterology; as Co-Founder, CFO of Cornerstones Health, Inc. (non-profit); and as Co-Founder of GoDuRn, LLC.

Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory board and is a consultant for AbbVie Inc.; Allergan; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Disclosures were obtained from the USF Health staff: No disclosures to report.

CME Outfitters, LLC, USF Health, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

MM-096-102819-90